INDEX TO VOLUME 85

Abdominal surgery, cough following, A13–16
Abdullah, A. K., 111–116
Adcock, J. J., A43–46
Adhesion molecules and inflammation, 91–99
β_2-Adrenergic agonist, 393–399
β-Adrenoceptor agonists, long-acting, 5–9
Agnew, J. E., A23–26
β-Agonists, 359–363
AIDS, cytomegalovirus pneumonia in, 437–439
Airflow limitation
  reversibility; steroid trials, 295–299
  in sarcoidosis, 59–64
Airflow obstruction and mortality, 27–35
Airlie, M. A. A., 517–520
Airways narrowing
  endobronchial, sarcoidosis presenting as, 425–426
  and nebulised pentamidine isethionate, 527–531
Airway resistance and mechanical stimulation of canine respiratory tract, A67–68
Ajarim, D. S. S., 81–83
Al-Hajjaj, M. S., 111–116
Al Jarad, N., 203–208
Allergens
  asthmatic responses to, 401–406
  avoidance in childhood asthma, 101–105
  late phase nasal reactions, 247–249
Allergic rhinitis, inflammatory cells in, 259–261
Al-Orainey, I. O., 111–116
Alveolitis, sulphasalazine-induced, recovery of lung function in, 73–75
Amoxycillin and bronchitis, 301–308
Anderson, J. W., A57–60
Anderson, K., 495–500
Antigens, inhaled, asthmatic response to, 393–399
Arrowsmith, J., 313–317
Asbestos exposure, 344–346
Asbestosis-induced pleural disease; CT assessment, 203–208
Aspiration reflex can reverse hypoxic apnoea in cats, A61–65
Asthma, 343–344
  acute, 487–493
  in adults
    CDAP breath sounds analysis, 125–131
    preventative therapy, 355–357
  β-agonists, 359–363
  allergen responses, 401–406
  autoantibodies to recombinant lipocortin-1 in, 121–124
  beclomethasone dipropionate, 401–406
  breath sounds analysis by CDAP, 125–131
  cardio-respiratory responses to exercise, 413–420
  and high dose corticosteroids, 501–510, 511–516
  diurnal variation of lung mechanics, 285–289
  hypothalamo-pituitary-adrenal axis suppression, 501–510, 511–516
  inhaled antigen response, 393–399
  ipratropium bromide, nebulized, 517–520
  Living with Asthma Questionnaire, B13–16
  lung hyperinflation in children, 379–382
  lymphocytes in, 87–90
  management
    in accident and emergency department, 373–377
    in the early 1990s, 353–354
  nebulizers, 359–363
  patient education and self-management, 457–462
  peak flow measurement, 457–462
  persistent, chronic, 359–363
  and pregnancy, 451–452
  recovery from, 487–493
  recognition and management, 463–474
  referral to hospital specialist, 453–455
  reversible T-wave abnormality, 195–201
  salbutamol, 401–406
  severe, acute, 195–201, 413–420, 463–474, 517–520
  steroids, 359–363
  symptoms, and coughing, A7–12
  see also Childhood asthma
Atopy; genetic basis, 351–352
Audit
  in respiratory medicine, B47–51
  tuberculosis contact tracing, 421–424
Australia, *Mycobacterium kansasii* infection in, 213–218
Ayres, J. G., 170

Bacci, E., 401–406
Baldwin, D. R., 21–25
Banham, S. W., 223–227
Barber, D., 535–537
Barnes, P. J., 121–124, 355–357
Baveystock, C. M., B25–31
Beclomethasone dipropionate, 401–406
Beesley, J., 389–392
Beňačka, R., A61–65
Bener, A. B., 111–116
Benson, M. K., 195–201
Berg, J. D., 21–25
Bhopal gas disaster victim, 539–541
Bitsakou, H., A7–12
Bjermer, L., 229–234
Blundell, G., 501–510, 511–516
BOOP, 177–178
  unilateral, 159–161
Boulet, L.-P., 487–493
Box, K., 71–72
Boyd, G., 495–500
Boyle, I. T., 223–227
Brachytherapy, 263–265
Branthwaite, M. A., 431–433
Bravo, M., 479–485
Breath sound analysis using CDAP, 125–131
Bredin, C. P., 77–79
Brewis, R. A. L., 457–462
British Thoracic Society Research Committee, 319–323
Britton, J., 151–153
Britton, M., 337–338
Bronchiectasis
  inflammation: systemic effects, 521–525
  lower, and endobronchial lipoma, 71–72
Bronchiolar narrowing and occlusion in sarcoidosis, 65–67
Bronchiolitis obliterans, 177–178
  and *Mycoplasma* pneumoniae, 535–537
Bronchiolitis obliterans organizing pneumonia *see* BOOP
Bronchitis, 343–344
  amoxycillin, 301–308
  cefaclor, 301–308
Bronchoalveolar lavage
  neutrophilia and parainfluenza 3 virus infection, 159–161
  and sarcoidosis, 229–234
Bronchoconstriction, reflex, and regional sensitivity of the respiratory tract, A47–50
Bronchodilator effect of salbutamol in children, 325–326
Brown, P. H., 501–510, 511–516
Buckingham, K., B34
Buckley, B. M., 21–25
Bucknall, C. E., 453–455
Bull, A. D., 327–329
Buxton, M. J., B35, B36, B43–46
Byfield, S. P., 275–280

Cafferkey, M. T., 383–388
Campbell, I. A., 155–157
Campbell, J. H., 223–227
Cancer
  brachytherapy, 263–265
  endobronchial laser therapy, 263–265
  malignant pleural mesothelioma, 255–256

metastasis from granulosa cell tumour of the ovary, 327–329
mimicked by endobronchial tuberculosis, 107–109
platelet-derived growth factor, 479–485
pulmonary artery leiomyosarcoma, 337–338
pulmonary metastases from ovarian cystadenomata, 147–150
and quality of life, B7–11
spontaneous pneumothorax in metastatic choriocarcinoma, 81–83
symptomatic hypercalcaemia in, 223–227
synovial cell sarcoma, 533–534
Canine respiratory tract, mechanical stimulation and nasal vascular and airway resistance, A67–68
Capsaicin
inhaled, pharmacology of, A31–34
mechanism of action, A35–41
Cardio-respiratory response to exercise, following asthma treatment, 413–420
Carič, D., A7–12
Carr, B., 185–187
Cats, hypoxic apnoea reversed by aspiration reflex in, A61–65
Cavan, D. A., 257–258
Cayton, R. M., 257–258, 413–420
CDAP breath sound analysis in children and adults, 125–131
Cefaclor and bronchitis, 301–308
Chamberlain-Webber, R., 313–317
Chan, H. S., 69–70
Chan, J. C., 339, 521–525
Chandra, H., 539–541
Chemotherapy for pulmonary tuberculosis, 291–294
Chest clinic, theophylline analysis at, 21–25
Chest percussion in treatment of patients with copious sputum production, 45–51, 443
Chest wall deformity, 431–433
Chidley, K. E., 373–377
Childhood asthma
allergen avoidance in, 101–105
CDAP breath sounds analysis, 125–131
lung hyperinflation in, 379–382
salbutamol via the Volumatic, 325–326
Children, tonsil core bacteriology, 383–388
Choriocarcinoma, metastatic, spontaneous pneumothorax in, 81–83
Chronic obstructive airways disease
nebulizer therapy, 281–284
reversibility tests, 281–284
Chronic Respiratory Questionnaire, B23–24
Chung, K. F., 5–9, 121–124
Clague, J. E., 301–308
Clarke, S. W., A23–26
Clinical decision-making and the role of health economics, B3–5
Coakley, D., 185–187
Cockcroft, D. W., 535–537
Cohen, M. A. H., 69–70
Collins, J. V., 295–299, 527–531
Community acquired lower respiratory tract infection in the elderly; prospective hospital study, 185–187
Computed tomography *see* CT
Computer digitized airway phonopneumography *see* CDAP
Conner, B., 125–131
Connolly, C. K., 53–58, 343–344
Continuous positive airway pressure *see* CPAP
Controlled-release salbutamol, 495–500
Cooper, G. J., 327–329
COPD
component analysis of respiratory function tests, 37–43
inhaled therapy benefits, 447–449
Cordon, S. M., 139–145
Corticosteroids, 501–510, 511–516
Cough
following general anaesthesia and abdominal surgery, A13–16
regional mucus movement in human lungs, A23–26
regional sensitivity of respiratory tract, A47–50
and symptoms in asthma, A7–12
and veratrine-induced reflexes, A51–55
Cough reflex, A3–5
and peripheral opioid receptors, A43–46
Cowie, J., 435–436, 533–534
CPAP ventilation in *Pneumocystis carinii* pneumonia, 133–138
Crompton, G. K., 501–510, 511–516
Cryptogenic organizing pneumonitis, 177–178
and rheumatoid arthritis, 243–246
CT
asbestos-induced pleural disease, 203–208
Bhopal gas disaster victim, 539–541
Cundall, D. B., 475–477
Cystic fibrosis
inflammatory markers in, 139–145
and patient information, 389–392
Cytomegalovirus pneumonia
in AIDS patient, 437–439
ganciclovir treatment, 437–439

Dahlbäck, M., A47–50
Darbyshire, J. H., 275–280
Davies, P. D. O., 175–176, 219–222
Davies, R. J., 247–249, 259–261, 301–308, 349
Demedts, M., 107–109, 333–335
Dente, F. L., 401–406
Diabetes and lung function, 257–258
Diethylcarbamazine and tropical eosinophilia, 17–20
Dilworth, J. P., A13–16
Donič, V., A61–65
Donnelly, S. C., 77–79
Dose-response slope, 365–371
Douglas, J. G., 71–72
Douglas, N. J., 517–620
du Bois, R. M., 177–178, 243–246

ECG, reversible T-wave abnormality in severe acute asthma, 195–201
Economic evaluation studies, B43–46
Economics, health; role in clinical decision-making, B3–5
Efthimiou, J., 195–201
Eiser, N., 393–399
Elderly patients
community acquired lower respiratory tract infection, 185–187
endobronchial tuberculosis mimicking lung cancer in, 107–109
Elegant, V. A., B34, B35, B39–41
El-Kassimi, F. A., 111–116
Elliott, M. W., 431–433
El-Soussi, M., 533–534
Elwood, R. K., 251–253
Empyema, post-pneumonectomy, late-onset, manifesting as tracheal stenosis, 333–335
Endobronchial biopsy positive sarcoidosis, 229–234
Endobronchial laser therapy, 263–265
Endobronchial lipoma and lobar bronchiectasis, 71–72
Endobronchial sarcoidosis presenting as severe upper airways narrowing, 425–426
Endobronchial tuberculosis mimicking lung cancer in elderly patients, 107–109
Engelaar, D., 333–335
Eosinophilia, tropical, and diethylcarbamazine, 17–20
Esmonde, T. F. G., 421–424
Ethambutol, ocular toxicity of, 151–153
Everett, L., 379–382
Exercise after asthma treatment, cardio-respiratory response to, 413, 420

Fabbri, L. M., 401–406
Fagan, A. M., 163–165
Feher, M. D., 295–299
Ferguson, H., 247–249
Fibrosis, 267–273
Flenley, D. C., 517–520
Flower, R. J., 121–124
Forced expiration technique (FET) and regional mucus movement in human lungs, A23–26
Forder, A. A., 11–16
Formoterol, 169–171
Freeman, D. J., 383–388

Freeman, W., 257–258, 413–420
Fuller, R. W., A31–34

Gaffney, R. J., 383–388
Gallon, A., 45–51
Ganciclovir, 437–439
Gazzard, B., 527–531
Geddes, D. M, B7–11, B33, B34
Genetic basis of atopy, 351–352
Giant cell tumour of a rib, 435–436
Giuntini, C., 401–406
Godolphin, J. L., 121–124
Gould, G. A., 517–520
Goulding, N. J., 121–124
Granulomatosis, Wegener's, and salmonella lung abscess, 339–341
Granulosa cell tumour of the ovary, metastasis from, 327–329
Green, C. P., 325–326
Green, S., 189–194
Greening, A. P., 495–500, 501–510, 511–516
Greenough, A., 189–194, 235–237, 379–382
Gribbin, H., 463–474
Guyatt, G. H., B17–21
Guz, A., A27–30

Hakkarainen, T., 159–161
Hames, A., 389–392
Hammond, J. M. J., 11–16
Hansson, L., A47–50
Harakati, M. S., 81–83
Harcombe, A., 151–153
Harrison, B. D. W., 59–64, 65–67, 353–354, 463–474, B47–51, B57
Hasani, A., A23–26
Hassan, A. B., 195–201
Hathaway, T., A17–21
Health economics: role in clinical decision-making, B3–5
Heart-lung transplantation, pulmonary reflexes after, A17–21
Hemoptysis, diagnosis of *Schistosoma japonicum* in a patient with, 331–332
Hendra, T. J., 435–436
Herdman, M. J., 301–308
Higenbottam, T., A17–21
Hiller, E. J., 139–145
Histamine H1-receptor antagonists, 393–399
Hnizdo, E., 27–35
Hogan, J. M., 77–79
Holgate, S. T., 91–99, 373–377
Holloway, L. J., 147–150
Hong Kong: tuberculosis in immigrants from South East Asia, 219–222
Horner, R. L., A27–30
Horsfield, N., 291–294
Howell, J. B. L., B1, B33, B34, B57, B59
Hutchcroft, B. J., B33
Hyland, M. E., B13–16, B34, B35, B36
Hypercalcaemia in lung cancer, 223–227
Hypothalamo-pituitary-adrenal axis suppression, 501–510, 511–516
Hypoxic apnoea reversal by aspiration reflex in cats, A61–65

Ind, P. W., 73–75
Infants, pre-term, paradoxical response to nebulized ipratropium bromide, 189–194
Inflammation
  and adhesion molecules, 91–99
  effects in bronchiectasis, 521–525
  chronic, 267–273
Inflammatory cells in allergic rhinitis, 259–261
Inflammatory markers in cystic fibrosis, 139–145
Intensive care management of *Klebsiella pneumoniae*, 11–16
Ip, M., 521–525
Ipratropium bromide, nebulized
  in acute severe asthma, 517–520
  in pre-term infants, 189–194

Jayanthi, V., 179–183
Jeffrey, A. A., 517–520
Jeffrey, R. R., 71–72
Jenkins, S. C., 309–311
John, P. J., 170–171
Jones, P. C., 281–284
Jones, P. W., B25–31, B33, B34, B35, B36
Junge, J., 437–439

Kamat, S. R., 539–541
Karlsson, J.-A., A47–50
Kava, T., 159–161
Kay, B., 87–90
Keane, C., 185–187
Keller, J., B17–21
Kennedy, A. H., 327–329
Kenney, I. J., 117–119
Kerr, K. M., 71–72
Kilburn, K. H., 345–346
Kinnear, W., 151–153
Klebsiella pneumoniae
  community-acquired, intensive care management of, 11–16
  pneumopyopericardium in, 427–429
Korpas, J., A3–5

Lal, S., 85
Lam, W. K., 521–525
Lambourne, A., 111–116
Lambrechts, M., 107–109
Lane, D. J., 359–363
Lant, A. F., 295–299
Laryngeal receptors, response to water solutions, A57–60
Larynx, sudden death from non-Hodgkin's lymphoma of, 77–79
Laser therapy, endobronchial, 263–265
Leigh, T. R., 527–531
Leiomyosarcoma, pulmonary artery, 337–338
Linton, D. M., 11–16
Liong, E., 521–525
Lipocortin-1, recombinant, circulating autoantibodies to, in asthma, 121–124
Lipoma, endobronchial, and lobar bronchiectasis, 71–72
Living with Asthma Questionnaire, B13–16
Lock, S. H., 407–412
Lowry, R., A17–21
Lozewicz, S., 259–261
Lundgren, J. D., 437–439
Lung, M. A., A67–68
Lung
  asbestosis-induced pleural disease, 203–208
  chronic disease: functional status measurement, B17–21
  diurnal variation of mechanics, in asthma, 285–289
  endobronchial tuberculosis mimicking cancer, in elderly patients, 107–109
  hyperinflation in young asthmatics, 379–382
  macrophages, 267–273
  pulmonary reflexes after heart-lung transplantation, A17–21
  regional mucus movement and coughing/FET, A23–26
  Samonella abscess, 339–341
  see also Cancer
Lung function
  and asbestosis-induced pleural disease, 203–208
  and diabetes, 257–258
  and mild obesity, 309–311
  and neonatal respiratory distress, 235–237
  in sulphasalozine-induced alveolitis, 73–75
  in tropical eosinophilia, 17–20
Lutz, C., 125–131
Lymphocytes in asthma, 87–90
Lymphoma, non-Hodgkin's, of the larynx, sudden death from, 77–79

MaMcCann, B. G., 65–67
McCarthy, O. R., 291–294
Macfarlane, J., 151–153

McHardy, G. J. R., A7–12
Mackay, A. D., 21–25
Mackay, J. B., 147–150
Macrophages, 267–273
Mahashur, A. A., 170–171
Makino, M., 37–43
Mapp, C. E., 401–406
Mathew, O. P., A57–60
Mathiesen, L. R., 437–439
Matsumoto, H., 37–43
Matusiewicz, S. P., 495–500
Mayberry, J. F., 179–183
Medical Research Council Cardiothoracic Epidemiology Group, 319–323
Meningocele, intrathoracic, and neurofibromatosis, 163–165
Metastasis from a granulosa cell tumour of the ovary, 327–329
Metastatic choriocarcinoma, spontaneous pneumothorax in, 81–83
Methacholine, 365–371
Middleton, W. G., 255–256
Miller, R. F., 133–138
Milot, J., 487–493
Mitchell-Heggs, B35
Mohammed, A. F., 495–500
Montefort, S., 91–99
Moore-Gillon, J. C., 451–452
Morgan, M. D. L., B23–24, B31, B34, B35, B36, B57
Morrison, J. F. J., 281–284, 285–289
Mortality, relevance of airflow obstruction and mucus hypertension, 27–35
Moss, S. F., 73–75
Mouth pressures, maximal, in sitting and half-lying positions, in normal subjects, 209–211
Moxham, J., 309–311
Mucus hypersecretion and mortality, 27–35
Mucus movement in human lungs, effect of coughing/FET, A23–26
Muers, M. F., 281–284
Mulvihill, E., 185–187
Munglani, R., 117–119
Murray, M. E., 425–426
Mycobacterium kansasii infection in Australia, 213–218
Mycoplasma pneumonia and bronchiolitis obliterans, 535–537

Nagyova, B., A51–55
Nakano, H., 37–43
Narayanan, P. S., 539–541
Nasal reactions, late phase, 247–249
Nasal vascular resistance, and mechanical stimulation of canine respiratory tract, A67–68
Nebulized ipratropium bromide, 517–520
  in pre-term infants, 189–194
Nebulized pentamidine isethionate, 527–531
Nebulizer therapy
  in chronic obstructive airways disease, 281–284
  in chronic persistent asthma, 359–363
  at home, 1–3, 281–284
Nedocromil sodium, 85
Nelson, R., 389–392
Neonatal respiratory distress and lung function at follow-up, 235–237
Neuberger, Rabbi J., B34, B35, B53–56, B57, B58
Neurofibromatosis and intrathoracic meningocele, 163–165
Neuromuscular disease, 431–433
Neuropsychiatric symptoms, 431–433
Neville, E., 463–474
Ng, G. Y., 209–211
Nicotine chewing gum, 155–157
Nisar, M., 175–176, 219–222
N_2 inhalation, hypoxic apnoea induced by, in cats, A61–65
Nogradi, S., B17–21
Non-Hodgkin's lymphoma of the larynx, sudden death from, 77–79
Norman, D., 139–145
Nunn, A. J., 275–280

Obesity, mild, and lung function, 309–311
Occult respiratory failure and neuromuscular disease, 431–433
O'Connor, B., 121–124
Ocular toxicity of ethambutol, 151–153
O'Donnell, M. J., 257–258
O'Driscoll, R., 1–3, B33
O'Leary, C., 533–534
O'Leary, C. P., 435–436
O'Neill, T. P., A35–41
Onodera, S., 37–43
Opioid receptors, peripheral, and cough reflex, A43–46
Ormerod, L. P., 239–242, 275–280, 291–294
Ormerod, O., 195–201
Ovarian cystadenomata, pulmonary metastases from, 147–150
Ovarian granulosa cell tumour, metastases from, 327–329
Oxygen, portable, 407–412

Packe, G. E., 413–420
Paediatric parapneumonic effusions, 117–119
Paggiaro, P. L., 401–406
Pang, S. C., 213–218
Parainfluenza 3 virus infection, 159–161
Parapneumonic effusions, paediatric, 117–119
Parasympathetic nervous system and lung mechanics in asthma, 285–289
Pardo, A., 479–485
Parkes, A., 257–258
Parnell, D., 331–332
Partridge, M. R., 353–354
Patients, hospital, smoking cessation in, 155–157
Patient's viewpoint, B53–56
Patterson, A., B36
Paul, E. A., 407–412
Pavia, D., A23–26
Pearson, M. C., 203–208, 344–345
Pearson, S. B., 285–289, 475–477
PEEP ventilation and pulmonary oedema, 69–70
Pentamidine isethionate, nebulized, 527–531
Perämäki, E., 159–161
Petheram, I. S., 421–424
Pharmacology of inhaled capsaicin in humans, A31–34
Pien, F. D., 331–332
Pierce, R. J., 263–265
Platelet-derived growth factor, 479–485
Pleural disease, asbestos-induced; CT assessment, 203–208
Pneumocystis carinii pneumonia, 133–138
Pneumonia
  and bronchiolitis obliterans, 535–537
  community-acquired, 313–317
  cytomegalovirus, in AIDS patients, 437–439
  Klebsiella, 11–16, 427–429
  Mycoplasma, 535–537
  Pneumocystis carinii, 133–138
  routine microbial investigation, 313–317
Pneumopyopericardium and *Klebsiella* pneumonia, 427–429
Pneumothoraces, bilateral, spontaneous, from synovial cell sarcoma, 533–534
Pneumothorax
  recurrent, and malignant pleural mesothelioma, 255–256
  spontaneous, in metastatic choriocarcinoma, 81–83
Podgorski, M. R., 121–124
Pool, J., 379–383
Portable oxygen therapy, 407–412
Postma, D. S., 447–449
Postoperative coughing, A13–16
Potgieter, P. D., 11–16
Poulakis, N., 203–208
Pounsford, J. C., A13–16
Power, G., 53–58
Prabhakar, R., 17–20
Prabhu, M. B., 535–537
Pregnancy and asthma, 451–452
Prescott, R. J., 155–157, 239–242
Price, J. F., 325–326, 379–382
Probert, C. S. J., 179–183
Pulmonary artery leiomyosarcoma, 337–338

Pulmonary function, 343–344
  and work done, 53–58
  in sarcoidosis, 59–64
Pulmonary hypertension, 443–445
Pulmonary metastases from 'benign' mucinous ovarian cystadenomata, 147–150
Pulmonary oedema and PEEP ventilation, 69–70
Pulmonary reflexes after human heart-lung transplantation, A17–21
Pulmonary tuberculosis
  chemotherapy for, 291–294
  management in England and Wales, 319–323

Quality of life
  in lung cancer, B7–11
  multi-centre trials, B39–41
Quirk, F. H., B25–31

Rabe, K. F., 5–9
Radiography, 203–208
Raffin, T. A., 339–341
Rahamim, J., 435–436
Ralston, S., 223–227
Rao, K. V. K., 17–20
Rayner, R. J., 139–145
Rees, J. H., 243–246
Respiratory failure
  occult, and neuromuscular disease, 431–433
  Pneumocystis carinii pneumonia, 133–138
  and tracheal stenosis, 333–335
Respiratory function tests, principal component analysis, in COPD, 37–43
Respiratory tract
  canine, mechanical stimulation of, and nasal vascular and airway obstruction, A67–68
  regional sensitivity; cough and reflex bronchoconstriction, A47–50
Rheumatoid arthritis and cryptogenic organising pneumonitis, 243–246
Ribs
  giant cell tumour, 435–436
  tuberculosis, 251–253
Richardson, W. N., 169–171
Rogiers, Ph., 333–335
Romppanen, T., 159–161
Rosenhall, L., 229–234
Rubens, M. B., 203–208
Rubio, H., 479–485
Rudd, R. M., 203–208, 291–294, 407–412
Ryan, D., B57

St George's Respiratory Questionnaire, B25–31
Salazar, M., 479–485
Salbutamol
  and asthmatic response to allergen, 401–406
  in chronic airflow obstruction, 495–500
  controlled-release, 495–500
  via Volumatic in children, 325–326
Salmi, I., 159–161
Salmonella lung abscess, 339–341
Sanderson, M., 337–338
Sankaran, K., 17–20
Sant'Ambrogio, F. B., A57–60
Sant'Ambrogio, G., A57–60
Santhosh-Kumar, C. R., 81–83
Sarcoidosis
  airflow limitation in, 59–64
  bronchiolar narrowing and occlusion, 65–67
  endobronchial, 229–234, 425–426
Sarcoma, synovial cell, 533–534
Sarkar, P. K., 163–165
Sasaki, N., 37–43
Sastry, C. V., 427–429
Saudi Arabia, tuberculin survey, 111–116
Schistosoma japonicum, bronchoscopic diagnosis of, 331–332
Scrimgeour, E. M., 427–429
Selman, M., 479–485
Semple, S. J. G., 133–138
Senn, S., 169–171
Seppälä, O.-P., 365–371
Shale, D. J., 139–145
Sharland, P. R., 121–124
Sharma, S., 539–541
Shaw, M., 169–171
Shaw, R. J., 267–273
Shaylor, J. M., 59–64
Sheppard, M. N., 243–246
Sher, K. S., 179–183
Shimazu, C., 331–332
Sibbald, B., 351–352
Singer, J., B17–21
Situnayake, R. D., 255–256
Slate, R. A., 373–377
Smoking
  cessation in hospital patients, 155–157
  and prevention, 179–183
South East Asia, tuberculosis in immigrants from, 219–222
Sputum production, copious, and chest percussion, 45–51, 443
Sriramachari, S., 539–541
Steroids, 295–299, 359–363
Stjernberg, N., 229–234
Stokes, M. J., 209–211
Stokes, T. C., 59–64, 425–426
Sudden death from B-cell non-Hodgkin's lymphoma of the larynx, 77–79
Sulphasalazine-induced alveolitis, recovery of lung function in, 73–75
Sykes, A. P., 170
Synovial cell sarcoma, 533–534

Tabaqchali, S., 301–308
Tack, J., 107–109
Talini, D., 401–406
Tatar, M., A51–55
Teale, C., 281–284, 475–477
Testi, R., 401–406
Theophylline analysis at the chest clinic, 21–25
Thomson, N. C., 495–500
Thunell, M., 229–234
Tinkelman, D. G., 125–131
Tjeder-Burton, S. M., 155–157
Tkáčová, R., A61–65
Tomori, Z., A61–65
Tonsil care bacteriology in adults and children, 383–388
Town, G. I., 373–377
Townsend, M., B17–21
Tracheal stenosis and late-onset post-pneumonectomy, 333–335
Tracheobronchial narrowing, 263–265
Transplantation, heart-lung, pumonary reflexes after, A17–21
Trigg, C. J., 301–308
Tuberculin survey in Saudi Arabia, 111–116
Tuberculosis
  and age, 275–280
  audit of contact tracing, 421–424
  in Bangladeshi patients, 275–280
  chemotherapy, 291–294
  compliance with treatment, 239–242
  drug regimens, 239–242
  endobronchial, mimicking lung cancer in elderly patients, 107–109
  and ethnic groups, 275–280
  in immigrants from South East Asia, 219–222
  on the increase?, 175–176, 545–546
  in Indian patients, 275–280
  management in England and Wales, 319–323
  in Pakistani patients, 275–280
  relapses, 239–242
  of the ribs, 251–253
  time of development in contacts, 475–477
Turcotte, H., 487–493
T-wave abnormality, reversible, in severe acute asthma, 195–201

Upper airway patency maintenance in man, A27–30

Vagaggini, B., 401–406
Van den Brande, P., 107–109
Van Mieghem, W., 333–335
Vàsquez, R., 479–485
Venkatesan, P., 17–20
Veratrine-induced reflexes and cough, A51–55
Vestbo, J., 437–439
Vijayan, V. K., 17–20, 539–541
Vijayaraghavan, R., 81–93
Volumatic spacer device, in children, 325–326

Walker, A., B34
Wallwork, J., A17–21
Walsh, J. B., 185–187
Walsh, M. A., 383–388
Wang, J. C. C., A67–68
Warner, J. A., 101–105
Warner, J. O., 101–105
Warshaw, R. H., 345–346
Water solutions of different osmolality and ionic composition; responses of laryngeal receptors, A57–60
Wedzicha, J. A., 407–412
Wegener's granulomatosis, 339–341
Whyte, K. F., 517–520
Widdicombe, J. G., A1, A3–5, A51–55
Wiebe, E. R., 251–253
Wiggins, J., 295–299, 527–531
Wiles, F. J., 27–35
Wilkes, A. R., 59–64
Wilks, M., 301–308
Wilkinson, G. A. L., 327–329
Williams, A., B3–5, B33, B34, B36
Williams, C. S. D., 219–222
Williams, I., 313–317
Wiseman, M. S., 139–145
Wollmer, P., A47–50
Wong, C. F., 69–70
Wood-Baker, R., 373–377
Woodhead, M. A., 177–178, 243–246, 313–317
Wooding, S., 313–317
Work done and pulmonary function, 53–58

Yamamura, K., 37–43
Young, S., A7–12
Yuksel, B., 189–194, 235–237